|
Synonyms: Cejemly® (China) | CS-1001 | CS1001 | WBP-3155 | WBP3155
sugemalimab is an approved drug (China (2021), EMA (2021))
Compound class:
Antibody
Comment: Sugemalimab is a fully human, high-affinity anti-programmed death ligand 1 (PD-L1) IgG4 monoclonal antibody. It is a checkpoint inhibitor class immuno therapeutic. In vitro, it competitively blocks the binding of human PD-L1 to PD-1 and CD80, and it induces T lymphocyte proliferation and enhances antitumour immunity [2].
|
Classification  |
|
| Compound class | Antibody |
| Ligand families/groups | Immune checkpoint modulators |
| Approved drug? | Yes (China (2021), EMA (2021)) |
| Approved drug? | Yes. China (2021) |
| International Nonproprietary Names |
|
| INN number | INN |
| 11330 | sugemalimab |
| Synonyms |
| Cejemly® (China) | CS-1001 | CS1001 | WBP-3155 | WBP3155 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 1031 |
| Other databases | |
| GtoPdb PubChem SID | 479821133 |
| Search PubMed clinical trials | sugemalimab |
| Search PubMed titles | sugemalimab |
| Search PubMed titles/abstracts | sugemalimab |
